Cyclo Therapeutics Faces Potential Delisting Due to Failure to Hold Annual Shareholders MeetingUNITED STATES SECURITIES AND EXCHANGE COMMISSION, Washington, D.C. – January 10, 2025 – ON January 10, 2025, Cyclo Therapeutics, Inc. (the “Company”) recei

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cyclo Therapeutics’s 8K filing here.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.